Topics:

ASCO 2014 Colorectal Cancer

ASCO 2014 Colorectal Cancer

Cancer Network presents exclusive coverage of colorectal cancer from the American Society of Clinical Oncology (ASCO) annual meeting. We'll bring you reports and interviews as we cover the latest research, trials, and scientific advances that are changing the way colorectal cancer is managed and treated.

ASCO 2014 Colorectal Cancer

Consuming more than two servings of fish each week can reduce a person’s risk for recurrence of colorectal cancer, according to the results of a cross-sectional multinational study.

This slide show highlights some of the top studies and news on colorectal cancer to come out of the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago.

Maintenance treatment with capecitabine and bevacizumab after 6 cycles of CAPOX B is an effective treatment in patients with metastatic colorectal cancer, according to the final results of the CAIRO3 study.

Exposure to a preference-based mail and telephone navigation intervention increased colorectal cancer (CRC) screening adherence compared to a standard mailed intervention among African Americans.

First-line treatment with chemotherapy plus either bevacizumab or cetuximab resulted in equally effective outcomes for patients with metastatic colorectal cancer.

The role of oxaliplatin in early-stage rectal cancer may still be unclear, according to the differing disease-free survival results from two studies presented at the 2014 ASCO Annual Meeting.

Treatment with oxaliplatin-containing FOLFOX significantly improved the 3-year disease-free survival of select patients with curatively resected rectal cancer compared with treatment with 5-fluorouracil/leucovorin.

Pages

Subscribe to ASCO 2014 Colorectal Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.